Patrick Soon-Shiong: Complete Responses with NK Cell Therapy – the Power of the Bioshield Platform
Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X by ImmunityBio, adding:
“Complete responses with NK cell therapy. The power of the Bioshield platform.
A tumor agnostic chemo free paradigm change by treating the immune system. The lymphoma trial is open. Contact the Chan Soon-Shiong Institute for Medicine (CSSIFM) to enroll. Next news coming – glioblastoma.
The power of NK cells. After a single cycle of NK cells targeting the tumor, the patient with a rare lymphoma (WM) -90 percent of bone marrow infiltrated ( left PET scan) achieved a COMPLETE RESPONSE (right scan). Had failed all other therapy. The power of the BIOSHIELD platform.”
Quoting ImmunityBio’s post:
“We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenström lymphoma patients treated with our CD19 CAR-NK cell therapy.
Proceed to the video attached to the post.
More posts featuring Patrick Soon-Shiong.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023